First in class lateral meniscus prothesis to relieve pain and restore mobility f...
First in class lateral meniscus prothesis to relieve pain and restore mobility for KOA patients
ATRO Medical developed a revolutionary prothesis that quickly relieves pain and restores mobility for severe KOA patients with a dysfunctional lateral meniscus: Trammpolin. We offer a minimally invasive, low impact procedure that...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
RTI2018-094339-B-I00
DISEÑO DE LA FIJACION EN TRANSPLANTE DE MENISCO SIN PORCIONE...
61K€
Cerrado
EmboSure
Disruptive, drug free treatment of knee osteoarthritis using...
4M€
Cerrado
MetaBioMec
Biomechanics of menisci a multiscale experimental theoreti...
176K€
Cerrado
TOTAL.KNEE
Development of a new generation of knee prostheses with enha...
100K€
Cerrado
APRICOT
Anatomically Precise Revolutionary Implant for bone Conservi...
3M€
Cerrado
Información proyecto AL U KNEED
Duración del proyecto: 34 meses
Fecha Inicio: 2022-11-21
Fecha Fin: 2025-09-30
Líder del proyecto
ATRO MEDICAL BV
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
4M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
ATRO Medical developed a revolutionary prothesis that quickly relieves pain and restores mobility for severe KOA patients with a dysfunctional lateral meniscus: Trammpolin. We offer a minimally invasive, low impact procedure that postpones undesirable TKR and reduces KOA-related healthcare costs and medication dependency, while restoring full knee functioning. Our innovation is composed of a dual highly biocompatible polymer that carries the body weight and is uniquely shaped to reproduce the anatomical shape and mechanical properties of the native meniscus. The technology has proven itself for the medial meniscus and received the Breakthrough Device Designation of the US FDA in 2020. For successful market entry of our lateral Trammpolin in 2026, we aim to finalize our pre-clinical activities, conduct a FIH-study, and obtain CE-marking. In parallel we will perform a health economics analysis as a crucial step towards obtaining reimbursement for large scale uptake in the medical system.